Erlotinib is a drug used to treat advanced lung cancers that contain a mutation in the EGFR gene. It is typically given at a dose of 150 mg a day, taken orally (by mouth). However, after about a year of treatment, most patients experience continued growth of their cancer.
The purpose of this study is to evaluate a new dosing schedule for erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who have EGFR mutations. Computer modeling and laboratory studies suggest this new dosing schedule may be effective against the cancer for a longer period of time than the current dosing schedule. Patients will take a high dose of erlotinib on two days of the week and a low dose on each of the other five days of the week.